following a full submission
erlotinib (Tarceva®) is accepted for use within NHS Scotland.
Indication under review: first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
In patients with advanced or metastatic NSCLC with EGFR mutations, erlotinib was associated with significantly improved progression-free survival compared with platinum-based doublet chemotherapy regimens. There are no mature overall survival data.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of erlotinib. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland.
|Drug Name:||erlotinib (Tarceva)|
|SMC Drug ID:||749/11|
|Indication:||First line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR|
|Sub Category:||8.1 Cytotoxic drugs|
|Submission Type:||Full submission|
|Date Advice Published:||16 January 2012|